2022
DOI: 10.1101/2022.04.29.22274376
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

High-dimensional deconstruction of pancreatic ductal adenocarcinoma identifies tumor microenvironmental communities associated with survival

Abstract: Bulk and single-cell analyses of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) have revealed a largely immunosuppressive milieu. Thus far, efforts to utilize insights from TME features to facilitate more effective therapeutics have largely failed. Here, we performed single-cell RNA sequencing (scRNA-seq) on a cohort of treatment-naive PDAC time-of-diagnosis endoscopic ultrasound-guided fine needle biopsy samples (n=22) and surgical samples (n=6), integrated with 3 public datasets … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 40 publications
(84 reference statements)
0
3
0
Order By: Relevance
“…The presence of effector T cells in our cohort is consistent with previous studies of human and mouse autochthonous PDAC immune microenvironments in which activated, effector T cells were found ( 16 ). A previous preprint study with single-cell sequencing and meta-analysis in PDAC also identified cytolytic CD8 + T cells and their association with improved patient outcomes ( 17 ). Current T cell checkpoint therapy (such as anti–PD-1 antibody) has not been effective in PDAC ( 1 ); thus, additional immunotherapy will be needed to enhance the preexisting T cell activity ( 5 ).…”
Section: Discussionmentioning
confidence: 91%
“…The presence of effector T cells in our cohort is consistent with previous studies of human and mouse autochthonous PDAC immune microenvironments in which activated, effector T cells were found ( 16 ). A previous preprint study with single-cell sequencing and meta-analysis in PDAC also identified cytolytic CD8 + T cells and their association with improved patient outcomes ( 17 ). Current T cell checkpoint therapy (such as anti–PD-1 antibody) has not been effective in PDAC ( 1 ); thus, additional immunotherapy will be needed to enhance the preexisting T cell activity ( 5 ).…”
Section: Discussionmentioning
confidence: 91%
“…Iterative refinement of analyses to identify confounder subsets in the patient cohort can thus be instrumental to understand the underlying biology. For instance, the two major transcriptional subtypes of PDAC, basal‐like and classical, differ in survival outcomes [27] and baseline immune microenvironments [33,34], while male PDAC patients overall exhibit higher incidence [35], poorer outcomes [36], and increased TIMP‐1‐mediated hepatic metastasis [37]. Of note, IL‐6 itself has been directly implicated in sex differences in hepatocellular carcinoma [38] and oral squamous cell carcinoma [39], and immune differences in rheumatoid arthritis [40,41].…”
Section: Resultsmentioning
confidence: 99%
“…Iterative refinement of analyses to identify confounder subsets can thus be instrumental to understand underlying biology. For instance, molecular subtypes of PDAC (29) differ in their baseline immune microenvironments (30,31) while IL-6 itself has been implicated in sex-differences in the context of hepatocellular carcinoma (32). To test whether the involvement of IL-6 in key biological patterns (immune phenotypes, TME composition) was confounded within specific PDAC patient subsets, we applied parallel subgroup comparison under otherwise identical analytical conditions across global and regional analysis levels, leveraging all steps in the Hourglass workflow (Fig.…”
Section: Systematic Comparison Of Il-6 Effects Between Patient Subset...mentioning
confidence: 99%